EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Dong-A St (170900) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Dong-A St KRW 10,611, price KRW 34,950, upside -69.6%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7170900005

DA Some data Oct 1, 2026

Dong-A St

170900 · KO

Weakest SetupStrongly overvalued and low quality.

Low debt
Expensive Growth (revenue 5y +6.6 %/yr in KRW)
Thin margins · 1.0% net margin (TTM)
2.0% dividend yield · Watch coverage
Some data
Fair value 10,611 KRW · Strongly overvalued (−69.6%)
Quality 37/100
Negative free cash flow
Trails peers (3/10)
Narrow moat 23/100
Watch Dong-A St for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

83,714 KRW 32,000 KRW Fair Value 10,611 KRW May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.

How to read this chart

60‑month range 32,000 KRW – 83,714 KRW · fair‑value band 10,611 KRW – 22,752 KRW · the 34,950 KRW price screens above the 10,611 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.

Follow Dong-A St in your weekly email

Every Wednesday you see whether Dong-A St is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj.

Show more

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for ovarian hyperstimulation and anovulation; Growtropin II Inj./AQ /cartridge to treat growth failure due to an inadequate secretion of growth hormone and idiopathic short stature, small for gestational age, turner syndrome; Leucostim Inj. for neutropenia in patients receiving myelosuppressive chemotherapy; Mainta inj. for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel inj. to treat breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone tab. for use in functional dyspepsia treatment; Stillen tab/ Stillen 2X tab. to treat gastritis; Suganon tab./Sugamet XR tab. and Sugadapa tab./Sugatree XR tab for type 2 diabetes mellitus; DA-3880 PFS to treat renal anemia and darbepoetin-alfa; and Zydena tab. for erectile dysfunction treatment. The company also provides licensed-in and licensed-out drugs; and medical devices, which cover high-technology medical devices, custom-made products, and sets of artificial cardiac circuits for use in open-heart surgery. Dong-A ST Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.

Stock analysis

Dong-A St (170900) currently trades at 34,950 KRW, while our model-based Fair Value estimate is 10,611 KRW, 69.6% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 6 models at a data quality of 91/100, which puts the evidence level at medium.

Scenario range: 10,611 KRW (bear) to 22,752 KRW (bull), the price of 34,950 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Dong-A St reported revenue of 809B KRW in FY2025 versus 593B KRW in FY2021, a compound +8.1%/yr. Reported net income was −28.6B KRW in FY2025.

Key figures

Market cap 336B KRW (≈ $250M) · P/S ratio 0.39 · Dividend yield 2.0% · Net margin −3.5% · Return on equity 0.9% · Return on assets (EBIT) 0.4% · Operating margin 2.8% · Revenue (TTM) 861B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 36% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −70%, 170900 screens richer than that median.

Fair Value models

Bear 10,611 KRW Fair Value 10,611 KRW Bull 22,752 KRW
Price 34,950 KRW · Upside -69.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EV/EBITDA 22,230 KRW 34,371 KRW 46,513 KRW 66
NCAV (Graham) 33,323 KRW 44,652 KRW 66,645 KRW 54
All 2 models by family
Multiples
EV/EBITDA 22,230 KRW 34,371 KRW 46,513 KRW 66
Asset-Based
NCAV (Graham) 33,323 KRW 44,652 KRW 66,645 KRW 54

Open the full fair value analysis →

Notify me when 170900 reaches fair value

Put 170900 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 37/100

Of which business quality 35 · Market factors (momentum, volatility) 39

Profitability 20
Margins and returns on capital today
Quality Growth 44
Are margins and returns improving?
Cashflow 13
Earnings quality: real cash, not paper profit
Fin. Strength 33
Balance sheet, leverage, solvency risk
Investment 84
Disciplined investing over empire-building
Low Volatility 78
Calm price path (market factor)
Momentum 30
Price trend over the last 3–12 months (market factor)
52W Momentum 12
Distance to the 52-week high (market factor)
Net Issuance 49
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 41/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+15.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
Start year 2020 (pandemic). Over 10 years: +3.6% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
5.8% (2020) → 0.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

170900 screens overvalued: fair value 70% below the price. Compare with Merck KGaA →

Compare Dong-A St with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 602 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −69.6% · Bottom 25%
Profitability
Return on equity (TTM) 0.9% · Below median
Return on assets 1.2% · Below median
Net margin (TTM) 1.0% · Below median
Operating margin (TTM) 2.8% · Below median
Growth and dividend
Revenue growth 15.8% · Above median
Dividend yield (TTM) 2.0% · Above median
Balance sheet
Debt / equity 0.47× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

EV/EBITDA 2.4× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 16
FUTURE (revenue growth)79 · sector 24
PAST (return on equity)3 · sector 26
HEALTH (low debt)77 · sector 96
DIVIDEND (yield)40 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $17.86 $11.35 −36%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Dong-A St · Fair Value
10,611 KRW −70%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Dong-A St Fair Value". https://www.fairvalue-calculator.com/stock/170900

Frequently asked questions

Is Dong-A St (170900) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of 10,611 KRW versus a price of 34,950 KRW, about −70% upside (overvalued).
What is the fair value of 170900?
Our model-based fair value for Dong-A St is 10,611 KRW (as of Oct 1, 2026), built from audited fundamentals. The current price: 34,950 KRW.
What is the quality score of 170900?
Dong-A St has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dong-A St (170900)?
Our model-based price target is the fair value of 10,611 KRW (as of Oct 1, 2026) from 2 valuation models. Cautious scenario 10,611 KRW, optimistic scenario 22,752 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Dong-A St stock forecast for 2026?
Our models put fair value at 10,611 KRW, about −70% upside versus a price of 34,950 KRW (overvalued). Cautious scenario 10,611 KRW, optimistic scenario 22,752 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Dong-A St (170900)?
Dong-A St reported trailing-twelve-month revenue of about 861B KRW (latest available figure, as of Oct 1, 2026).
Does Dong-A St pay a dividend?
Dong-A St currently shows a dividend yield of about 2.00% relative to its recent price (as of Oct 1, 2026).
What is the intrinsic value of Dong-A St (170900)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dong-A St it is 10,611 KRW per share (as of Oct 1, 2026), against a price of 34,950 KRW. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Dong-A St stock overvalued or undervalued in 2026?
As of Oct 1, 2026, 170900 trades above its calculated fair value: price 34,950 KRW, fair value 10,611 KRW, a gap of about −70% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 170900?
No. The price is what the market pays today (34,950 KRW); the fair value is what the company's own numbers justify (10,611 KRW). For Dong-A St the two are 24,339 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Dong-A St worth?
The market values Dong-A St at about 336B KRW (market capitalisation, as of Oct 1, 2026). Per share that is 34,950 KRW; our models calculate a fair value of 10,611 KRW per share.
What do the bullish and bearish scenarios say about 170900?
Our models span a range for Dong-A St: cautious scenario 10,611 KRW, base 10,611 KRW, optimistic 22,752 KRW per share (as of Oct 1, 2026, price 34,950 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Dong-A St (170900)?
Balance-sheet figures for Dong-A St (as of Oct 1, 2026): return on equity 0.9%, debt of 0.47 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 170900 from its 52-week high?
Dong-A St trades at 34,950 KRW, about 36% below its 52-week high of 54,197 KRW and 9% above the low of 32,000 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 10,611 KRW is for.
Which stocks are comparable to Dong-A St?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dong-A St stock attractive at the current price?
The data as of Oct 1, 2026: price 34,950 KRW, calculated fair value 10,611 KRW (−70%), Quality Score 37/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 170900 calculated?
We run Dong-A St through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 10,611 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1 % above its aggregate fair value. Dong-A St itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dong-A St (170900)?
The closing price on Oct 2, 2026 was 34,950 KRW. Our model-based fair value is 10,611 KRW, about −70% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dong-A St right now?
The price sits above even our optimistic bull case (22,752 KRW). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (10,611 KRW to 22,752 KRW) leaves room in how you read the outcome.

Key figures of Dong-A St

How large is the market capitalisation of Dong-A St (170900)?
The market capitalisation of Dong-A St is 336B KRW (≈ $250M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Dong-A St (170900)?
The price-to-sales ratio of Dong-A St is 0.39 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Dong-A St (170900)?
The dividend yield of Dong-A St is 2.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Dong-A St (170900)?
The net margin of Dong-A St is −3.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Dong-A St (170900)?
The return on equity (ROE) of Dong-A St is 0.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dong-A St (170900)?
On an EBIT basis the return on assets of Dong-A St is 0.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dong-A St (170900)?
The operating margin of Dong-A St is 2.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dong-A St (170900)?
Revenue at Dong-A St is growing +15.8% versus a year earlier (3y avg +8.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Dong-A St (170900)?
Earnings per share at Dong-A St are growing −64.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Dong-A St (170900) generate?
The free cash flow of Dong-A St is −7.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Dong-A St (170900) carry?
The net debt of Dong-A St is 366B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Dong-A St in the live analysis

One click puts Dong-A St on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.